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Abstract
In Europe alone, over 70 million people experience tinnitus; for seven million people, it creates a debilitating condition.
Despite its enormous socioeconomic relevance, progress in successfully treating the condition is somewhat limited. The
European Union has approved funding to create a pan-European tinnitus research collaboration network (2014–2018). The
goal of one working group is to establish an international standard for outcome measurements in clinical trials of tinnitus.
Importantly, this would enhance tinnitus research by informing sample-size calculations, enabling meta-analyses, and facil-
itating the identification of tinnitus subtypes, ultimately leading to improved treatments. The first meeting followed a work-
shop on “Agreed Standards for Measurement: An International Perspective” with invited talks on clinimetrics and existing
international initiatives to define core sets for outcome measurements in hearing loss (International classification of func-
tioning, disability, and health core sets for hearing loss) and eczema (Harmonizing outcome measures for eczema). Both
initiatives have taken an approach that clearly distinguishes the specification of what to measure from that of how to measure
it. Meeting delegates agreed on taking a step-wise roadmap for which the first output would be a consensus on what
outcome domains are essential for all trials. The working group seeks to embrace inclusivity and brings together clinicians,
tinnitus researchers, experts on clinical research methodology, statisticians, and representatives of the health industry. People
who experience tinnitus are another important participant group. This meeting report is a call to those stakeholders across
the globe to actively participate in the initiative.
Keywords
tinnitus, outcome assessment, standardization, measurement, clinical trial, population characteristics
Background
Tinnitus—a perception of phantom sound—is a wide-
spread auditory condition (Martinez, Wallenhorst,
McFerran, & Hall, 2014). A variety of risk factors
(hearing loss, diabetes, cardiovascular conditions, etc.)
1Nottingham Hearing Biomedical Research Unit, National Institute for
Health Research (NIHR), Nottingham, UK
2ENT Department of Hospital Cuf Infante Santo, Nova Medical School,
Lisbon, Portugal
31st Department of Otolaryngology, National and Kapodistrian University
of Athens, Athens, Greece
4Department of Otolaryngology, Laryngological Oncology, Audiology and
Phoniatrics, Medical University of Lodz, Lodz, Poland
5Charite´-Universita¨tsmedizin Berlin, Berlin, Germany
6Department of Otolaryngology, Charite´-Universita¨tsmedizin Berlin,
Berlin, Germany
7Department of Physiology and Pharmacology, Karolinska Institutet,
Stockholm, Sweden
8Otology and Hearing Group, Division of Clinical Neuroscience, School of
Medicine, University of Nottingham, Nottingham, UK
Corresponding author:
Deborah A. Hall, Nottingham Hearing Biomedical Research Unit, National
Institute for Health Research (NIHR), Ropewalk House, 113 The
Ropewalk, Nottingham NG1 5DU, UK.
Email: deborah.hall@nottingham.ac.uk
Creative Commons CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License
(http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further
permission provided the original work is attributed as specified on the SAGE and Open Access page (http://www.uk.sagepub.com/aboutus/openaccess.htm).
Trends in Amplification
2015, Vol. 19: 1–7
! The Author(s) 2015
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/2331216515580272
tia.sagepub.com
XML Template (2015) [10.4.2015–1:56pm] [1–7]
//blrnas3.glyph.com/cenpro/ApplicationFiles/Journals/SAGE/3B2/TIAJ/Vol00000/150005/APPFile/SG-TIAJ150005.3d (TIA) [INVALID Stage]
as well as potential mental comorbidities, such as depres-
sion or anxiety (Zirke et al., 2013), contribute to the
complexity of tinnitus. This complexity results in diag-
nostic and therapeutic challenges and also causes prob-
lems with the assessment of treatment outcome (Baguley,
McFerran, & Hall, 2013). Epidemiological studies per-
formed in Western industrialized countries have found
the prevalence rates of tinnitus to be roughly 10% of the
adult population. Of all individuals affected by tinnitus,
one third reported tinnitus as disturbing or very disturb-
ing (Baguley et al., 2013). The incidence of tinnitus
increases with age, as tinnitus closely accompanies any
form of hearing loss: in this case, age-related hearing
loss. For the industrialized countries, this translates
into an ever-growing number of tinnitus sufferers
(Martinez et al., 2014). Because of the high incidence
rate, the economic impact of tinnitus on the health-care
system is relatively large (Vio & Holme, 2005).
Two major factors contribute to the negative impact
of tinnitus on economy, health care, and the quality of
life of affected individuals: The first is a lack of a singu-
larly effective treatment, and the second is the variation
in routine daily practices applied by various clinical units
(see Baguley et al., 2013 for a review). Although pharma-
cotherapy for tinnitus is the subject of intense efforts
(Salvi, Lobarinas, & Sun, 2009), the development of an
international standard treatment protocol for chronic
tinnitus is still in its early stages. Several protocols
have been developed for tinnitus treatment such as
audiological management, tinnitus retraining therapy
(TRT), or cognitive behavioral therapy, but the protocol
application varies between practitioners, reflecting coun-
try-specific differences in health care or personal prefer-
ences. Of 335 studies that reported outcomes of TRT,
only one could be assessed in a systematic review, as it
was the only one that strictly followed the original proto-
col. As a result, a comparison between studies was
impossible (Phillips & McFerran, 2010). The situation
is slightly better for cognitive behavioral therapy,
where eight published trials have been included in a
Cochrane review and could be compared (Martinez-
Devesa, Waddell, Perera, & Theodoulou, 2007;
Martinez-Devesa, Perera, Theodoulou, & Waddell,
2010). Unfortunately, several discrepancies remained in
the outcome measurements, increasing the difficulties in
comparative analysis.
Why Are Outcome Measures for Clinical
Trials Important?
The fact that tinnitus is a complex symptom associated
with a variety of risk factors and affects not only audi-
tory but also emotional systems makes the choice of out-
comes challenging. Some studies or practitioners chose
to assess only audiological aspects of tinnitus, others
concentrated on psychological and mental health aspects
of tinnitus, and some used both types of domains. The
use of psychometric instruments widely differs among
published studies. The Tinnitus Handicap Inventory,
Tinnitus Handicap Questionnaire, Tinnitus Severity
Index, verbally administered TRT interview forms,
Iowa Tinnitus Handicap Questionnaire, Tinnitus
Severity Scale, Tinnitus Reaction Questionnaire, and
the Subjective Tinnitus Severity Scale are but a few ques-
tionnaires used to measure various parameters of ther-
apy outcomes (Phillips & McFerran, 2010).
Landgrebe et al. (2012; pp.116) described an outcome
measurement as “the single most important factor in
conducting a clinical trial in tinnitus.” Clinicians use
knowledge about how well treatment works when decid-
ing how best to treat their patients. Researchers create
this knowledge when they develop and test treatments.
Researchers discover the effect of treatments on patients
by measuring an outcome or a number of outcomes.
Outcomes have two facets. The first is the domain
defined as a distinct element (or topic) of tinnitus that
is deemed sufficiently important to be evaluated in all
clinical trials. Core outcome domains must be of equal
relevance to health professionals and to patients who
have first-hand experience of living with the condition.
Examples include how loud or how emotionally distress-
ing a patient may find his or her tinnitus. The second
facet is the outcome instrument defined as the tool used
to assess the domain. Outcome instruments should be
reliable, validated, and responsive to treatment-related
change. Making a quality-based evaluation about exist-
ing outcome instruments engages with a different branch
of science known as clinimetrics. This is a methodo-
logical discipline with a focus on the quality of measure-
ments in medical research and health-care practice (de
Vet, Terwee, Mokkink, & Knol, 2011).
Despite the high public health relevance of tinnitus, it
is still unclear which aspects of tinnitus are most relevant
for assessment in clinical trials and in clinical record
keeping. Different clinical trials that test treatments for
tinnitus often choose to measure different outcome
domains or select different outcome instruments pur-
ported to assess the same domain (Dobie, 1999; Hoare
& Hall, 2011; Hoare, Kowalkowski, Kang, & Hall, 2011;
Williamson, Altman, Blazeby, Clarke, & Gargon, 2012).
For example, if one tinnitus study measured loudness
and another measured emotional distress, then we
could not compare or combine results. Difficulties also
arise when researchers measuring several outcomes in a
study decide to publish their results for only some of
the outcomes (Clarke, 2007). This may happen when
the results for some of the outcomes are not what the
research team had hoped for. These actions present
problems for other researchers who would struggle to
work out exactly how effective a treatment is because
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they do not have full results from the study, and the
information they do have might be biased.
If all tinnitus studies used and reported results for the
same outcomes, they could be compared and combined.
This would make it much easier to make sense of all the
knowledge produced. A set of outcome domains and
instruments that has been agreed upon for a health con-
dition is called a Core Outcome Set (COS). A COS does
not necessitate that outcomes in a particular trial should
be restricted to only those in the COS. Rather, there is an
expectation that the core outcomes will be collected and
reported, but additional outcomes could be included as
well. Deciding which outcomes should be core outcomes
requires a great deal of discussion and so lends itself well
to an international effort.
TINNET—COSTAction BM1306: Better
Understanding the Heterogeneity of
Tinnitus to Improve and Develop New
Treatments
European Cooperation in Science and Technology
(COST, www.cost.eu) is an intergovernmental framework
aimed at facilitating the collaboration and networking of
scientists and researchers at European level. It was estab-
lished in 1971 by 19 member countries and currently
includes 35 member countries across Europe, and Israel
as a cooperating state. COST funds pan-European,
bottom-up networks of scientists and researchers across
all science and technology fields. These networks, called
COST Actions, promote international coordination of
nationally funded research. By fostering the networking
of researchers at an international level, COST enables
breakthrough scientific developments leading to new con-
cepts and products, thereby contributing to strengthening
Europe’s research and innovation capacities. COST’s
mission focuses, in particular, on the following:
. Building capacity by connecting high-quality scientific
communities throughout Europe and worldwide;
. Providing networking opportunities for early career
investigators;
. Increasing the impact of research on policy makers,
regulatory bodies, and national decision makers as
well as the private sector.
Through its inclusiveness, COST supports the integra-
tion of research communities, leverages national research
investments, and addresses issues of global relevance.
Every year, thousands of European scientists benefit
from being involved in COST Actions, allowing the
pooling of national research funding to achieve
common goals. As a precursor of advanced multidiscip-
linary research, COST anticipates and complements the
activities of EU Framework Programmes, constituting a
bridge toward the scientific communities of emerging
countries. In particular, COST Actions are also open
to participation by non-European scientists coming
from neighboring countries (e.g., Albania, Algeria,
Armenia, Azerbaijan, Belarus, Egypt, Georgia, Jordan,
Lebanon, Libya, Moldova, Montenegro, Morocco, the
Palestinian Authority, Russia, Syria, Tunisia, and
Ukraine) and from a number of international partner
countries. COST’s budget for networking activities has
traditionally been provided by successive EU RTD
Framework Programmes. COST is currently executed
by the European Science Foundation through the
COST Office on a mandate by the European
Commission, and the framework is governed by a
Committee of Senior Officials representing all its 35
member countries.
COST is currently funding a pan-European tinnitus
research collaboration network through COST Action
BM1306. The project is called TINNET, http://tinnet.
tinnitusresearch.net/, which stands for TINnitus research
NETwork TINNET’s main objective is to create a
research network for identifying pathophysiologically
and clinically meaningful subtypes of tinnitus and their
neurobiological underpinnings in order to develop and
improve new effective treatments for tinnitus. Within the
COST Action, Short-Term Scientific Missions are orga-
nized to allow participants to develop expertise in skills
required for the project and to strengthen European
collaboration.
Members also seek to learn from one another and to
disseminate their work through the organization of
workshops and conferences allowing tinnitus profes-
sionals to benefit from clinical and research training.
To provide longer term sustainability to the research,
there is an expectation that members will codevelop
grant proposals to national, European, and international
funding agencies. At present, the participants in the Cost
Action BM1306 come from 27 European countries (see
Figure 1).
TINNET comprises five working groups (WG): WG1
Clinical, WG2 Database, WG3 Neuroimaging, WG4
Genetics, and WG5 Outcomes. WG1 brings together
experts from different disciplines to develop easy and
meaningful guidelines for detailed clinical and pheno-
typic characterization of tinnitus cases and controls
(symptom scoring instruments and specific validated
self-report questionnaires). WG2 brings together clin-
icians, clinical trialists, data documentation specialists,
biostatisticians, and mathematicians to standardize
data management (statistical analysis) and quality con-
trol processes and to develop strategies for hypothesis-
driven and data-driven meta-analyses. WG3 concerns
neuroimaging. This group establishes Standard
Operating Procedures for data acquisition and analysis
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of brain imaging data in order to identify the neurobio-
logical mechanisms of the different forms of tinnitus.
WG4 concerns genetics. This group joins clinicians and
experts from molecular genetics, statistics, and bioinfor-
matics with the goal of creating a pan-European biobank
to study the underlying genetic basis of tinnitus.
Directly relevant to the purpose of this report, the
main goal of WG5 is to develop standards for tinnitus
clinical trials and outcome measurements in clinical trials
and everyday clinical practice. Adoption of the WG5
actions across different tinnitus groups and countries
would support data collection in a central database in
order to enable further meta-analysis of patient
responses to specific treatment options. The WG5 par-
ticipants are responsible for expanding and extending the
common central TINNET database to longitudinal data.
WG5 actions will result in implementation and dissem-
ination of guidelines and recommendations for assessing
tinnitus management.
At the time of writing, WG5 is an international group
of 27 clinicians (mainly specialists in otorhinolaryngol-
ogy and audiology), psychologists, clinical researchers,
and statisticians from 14 COST TINNET member coun-
tries. The participants have a wide range of expertise in
tinnitus assessment and management, including rando-
mized clinical trials. The group also has some experience
in systematic review, Delphi surveys, clinimetrics, guide-
line development, instrument development and evalu-
ation, and preclinical research.
Main Aims of the First Meeting: Workshop
and Meeting
Members of WG5 were invited to participate in a work-
shop and meeting that were held in Amsterdam on
November 13 and 14, 2014, respectively. The aim of
the workshop was to provide an overview of (a) existing
questionnaire tools for measuring tinnitus outcomes, (b)
the methodological approaches available to evaluate
the psychometric properties of those tools, and (c) the
experience of similar groups that had been through the
procedure of core set of outcome measures determin-
ation for other clinical entities (e.g., hearing loss,
eczema). Representatives presented talks on the meth-
odologies promoted by a number of different initiatives:
the COMET (Core Outcome Measures in Effectiveness
Trials, http://www.comet-initiative.org/about/overview),
initiative, the COSMIN (COnsensus-based Standards for
the selection of health Measurement INstruments, http://
www.cosmin.nl/cosmin-taxonomy.html) initiative, and
the ICF (International Classification of Functioning,
Disability and Health, http://www.icf-research-branch.
org/about-us/our-mission) Research Branch, a World
Health Organization collaborator. The purpose of
these presentations was to inform and familiarize WG5
participants about the current state-of-the-art regarding
tinnitus outcome measures, as well as to give an in-depth
overview of tools and methodologies that other groups
have used to determine core outcome measure sets. The
discussion was fruitful, and the participation was broad
and active.
One of the speakers at the workshop used the analogy
of a flower to describe the two-step process of defining a
COS (Figure 2). Step 1. Domain: This defines the process
of HOW to draw the flower by identifying how many
petals, and what domain each petal represents. Each
petal should relate to a topic or domain in which tinnitus
could have an effect (e.g., on quality of life, emotional
distress, or loudness). Step 1 seeks to achieve agreement
on what is important and essential. The process for Step
1 can be supported by the frameworks outlined by the
COMET initiative or by the WHO ICF branch. Step 2.
Measurement Tool: This defines the process of WHAT
will be the detail in the flower. Each petal needs to be
matched to some sort of instrument or measurement tool
(e.g., a questionnaire or a behavioral test). Step 2 seeks
to achieve a quality-based evaluation on what instrument
could be recommended and can be supported by the
checklist outlined by the COSMIN initiative. For many
TINNET members, this was quite a new way of thinking
about approaching the problem of measuring tinnitus.
The separation of how (domain) from what (measure-
ment tool) raised discussion across the group, but over-
all, the group was in favor of this two-step approach.
One advantage is that the first step avoids any direct
comparison between outcome measures and potential
disagreements over the psychometric validity of the dif-
ferent questionnaire tools.
Nineteen experts from 15 different countries partici-
pated in the subsequent meeting, including audiologists,
Figure 1. Twenty-seven participating countries across Europe:
Austria, Belgium, Cyprus, Czech Republic, Denmark, Finland,
France, fYR Macedonia, Germany, Greece, Ireland, Israel, Italy,
Lithuania, Malta, Netherlands, Norway, Poland, Portugal, Romania,
Serbia, Slovenia, Spain, Sweden, Switzerland, Turkey, and the
United Kingdom.
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otolaryngologists, psychologists, and researchers. The
aims of the WG5 meeting were to decide how the
group would work toward a COS determination,
the role of participants, and a set of milestones.
Methodologies presented the previous day were dis-
cussed and evaluated, decision-making procedures were
defined, stakeholders were identified, and ways to
approach them were proposed. Furthermore, partici-
pants discussed ways to engage clinical and patient
stakeholders across countries on an international level.
Summary of Key Discussion Points From
the Meeting
Members of the group agreed to be respectful of other
people’s knowledge, skills, and expertise, and to
approach the collaboration with an open, nonjudgmen-
tal, and prejudice-free mind. WG5 made the following
key decisions during the meeting:
1. Methodological approach: It was agreed that the pro-
cess of establishing standard outcome measurements
would use already existing methodology informed by
those working on other health conditions (Gargon,
Williamson, Altman, Blazeby, & Clarke, 2014). That
methodology would include a variant of the Delphi
survey starting off with a set of predefined domains
informed by previous work (e.g. Tyler & Baker, 1983).
2. Scope: The group agreed on establishing a COS for
all types of tinnitus relevant for an adult (but not
pediatric) population.
3. Group management:WG5 agreed unanimously on the
creation of a Core Project Team to advise and
manage the project. This group will be methodol-
ogy-oriented and include four to six individuals,
some of them being members of TINNET and
others being experts in the field of methodology
(where the expertise does not lie within TINNET).
In addition, WG5 agreed on the importance of a
patient representative(s) on the Core Project Team.
4. International reach: Although based in Europe and
managed by the European authorities, WG5 agreed
to extend the invitation to engage in WG5 activities
to all tinnitus researchers from all over the world and
to all relevant international and national organiza-
tions that are involved in tinnitus research, diagnosis,
or treatment.
5. Stakeholder groups: WG5 agreed on identifying and
actively engaging the following stakeholder groups:
academics who research tinnitus, clinicians dedicated
to tinnitus, founder and commissionaires of health
services, industry representatives, health insurance
Figure 2. A good analogy for the research process is that of creating a flower. Each petal of the flower denotes a core domain. Each of
those petals is associated with a particular measurement tool, denoted by the arrows. The identification of the domain set and outcome
measure set reflect two distinct and separate processes (how and what). The example here denotes five domains and associated tools.
There may be more or fewer depending on the outputs at each stage of the project, but the aim is to always nominate just one tool per
domain.
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companies, journal editors, tinnitus patients, and
regulatory body representatives.
Roadmap of the Overall Project
In summary, the overall ambition of the WG is to estab-
lish an international standard for outcome measure-
ments in clinical trials of tinnitus. The standard will be
achieved by a two-step effort to produce a COS of
domains and instruments that harmonize viewpoints
across both professional and patient stakeholder
groups. A roadmap has been proposed, which sets out
a provisional plan for delivery (Figure 3). This roadmap
reflects the two-step process with Stage 1 identifying and
agreeing on outcome domains, and Stage 2 identifying
and agreeing on outcome instruments. Stages 3 and 4 are
somewhat more speculative. They would not be required
if sufficient numbers of instruments passed the Stage 2
evaluation criteria set and if there was agreement to
adopt them into the COS. The short-term goal of the
WG is to achieve at least the first stage of the roadmap
supported by the present European Union funding.
To achieve a credible international standard requires
widespread engagement from stakeholders across the
globe, as well as transparent and rigorous methodology.
Our aspiration is that the standard will be adopted by all
workers in this field; thus, we acknowledge the import-
ance of enabling everyone to contribute their viewpoint
and for a consensus to be reached from those multiple
perspectives.
Plans for delivery of Stage 1 are as follows. A Core
Project Team will manage the project forward, meeting
regularly by teleconference. Members have not yet been
nominated, but the group will comprise the following
expertise from within the WG members: a clinician
with expertise in tinnitus, a researcher with expertise in
tinnitus, a researcher with experience in consensus meth-
odology, and a clinimetrician. In addition, the Core
Project Team will receive external advice from a
member of the Harmonizing Outcome Measures for
Eczema (HOME, www.homeforeczema.org/) initiative
The next tier of project management will include
national advocates acting on behalf of individual coun-
tries across the globe to ensure that as many cultural
perspectives as possible are represented. The role for
advocate participants in the project would be to translate
the Delphi survey from English into the native language,
engage with relevant national stakeholder groups
(including patient groups) to participate in the Delphi
survey, and contribute to dissemination.
Without external funding or a dedicated research
staff, the project currently relies on the enthusiasm and
motivation of its participants. Many of us see this as an
exciting new venture, which has the possibility to make a
ground-breaking contribution to the field.
Next Steps
The first meeting focused on defining the question, on
delineating the scope of the project and on agreeing on
some of the fundamental methodological principles to be
adopted. Prior to the second meeting, a small team of
members will conduct a systematic review to identify,
without bias, what outcome measurement tools have
been so far used in randomized controlled trials of
Figure 3. Anticipated roadmap for the project. COS¼Core Outcome Set.
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therapeutic interventions for tinnitus (http://www.
crd.york.ac.uk/PROSPERO/display_record.asp?ID=
CRD42015017525). The European Union grant will
fund a small number of short-term working visits to
facilitate this work over the next year.
The project is open to views from all stakeholders
interested in the development of COS for tinnitus.
There is a strong passion and shared optimism for work-
ing together and engaging with tinnitus experts outside
the European Union in order to achieve a true inter-
national consensus. Therefore, the WG particularly
encourages stakeholders from nations currently not rep-
resented to join the group, attend meetings, and partici-
pate in the Stage 1 Delphi survey. Participants from
countries outside the European Union are particularly
welcome to act as a national advocate for the project.
For more details, see http://tinnet.tinnitusresearch.net/
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